Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
MediWound Ltd. (MDWD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/26/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"YAVNE, Israel, September 26, 2023 -- MediWound Ltd. , a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense , through the Medical Technology Enterprise Consortium , has awarded MediWound additional funding to develop NexoBrid ® as a non-surgical solution for field-care burn treatment for the U.S. Army . The $6.5 million project budget will advance the development of a new, temperature stable formulation of NexoBrid, positioning it as the first-line non-surgical solution for treating severe burn injuries in pre-hospital settings. “We are honored to further our collaboration with the U.S. Department of Defense. Our shared vision of enhancing treatment outcomes for traumatic burns o..." |
|
| 08/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/15/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/15/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/02/2023 |
6-K
| Quarterly results |
| 07/17/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 07/10/2023 |
6-K
| Quarterly results |
| 07/03/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"YAVNE, Israel, July 3, 2023 – MediWound Ltd. , a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has received positive scientific advice from the Committee for Medicinal Products for Human Use within the European Medicines Agency related to the development plan for the company’s Phase III study of EscharEx in the treatment of Venous Leg Ulcers and to the overall data required for subsequent potential marketing authorization submission and commercialization. The CHMP notified the company that it concurs with the overall design of the proposed study, including its objectives, choice of study arms, patient population, inclusion/exclusion criteria, standardization of treatment, proposed primary, secondary, and s..." |
|
| 05/31/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/31/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/09/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/20/2023 |
6-K
| Quarterly results |
| 04/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/06/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/31/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/16/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/16/2023 |
POS EX
| Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]: |
| 03/16/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/16/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/16/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/16/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"6-K",
"Yavne, Israel, March 16, 2023 – MediWound Ltd. , a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound with a proven track record delivering positive business growth and profitable financial results in the technology and life sciences sect..." |
|
| 02/14/2023 |
SC 13G/A
| ROSENBERG LIOR reports a 4.3% stake in MediWound Ltd. |
| 02/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/13/2023 |
6-K
| Quarterly results |
| 02/08/2023 |
SC 13G
| Point72 Asset Management, L.P. reports a 8.9% stake in MediWound Ltd. |
| 02/07/2023 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 02/03/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 01/09/2023 |
6-K
| Quarterly results |
| 01/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/29/2022 |
6-K
| Quarterly results |
| 12/23/2022 |
6-K
| Quarterly results |
| 12/21/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/20/2022 |
6-K
| Quarterly results |
|
|
|